Please use this identifier to cite or link to this item:
http://hdl.handle.net/11375/8810
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.advisor | Buchanan, M.R. | en_US |
dc.contributor.author | Ryn-McKenna, Van Joanne | en_US |
dc.date.accessioned | 2014-06-18T16:44:04Z | - |
dc.date.available | 2014-06-18T16:44:04Z | - |
dc.date.created | 2011-03-18 | en_US |
dc.date.issued | 1991-04 | en_US |
dc.identifier.other | opendissertations/3984 | en_US |
dc.identifier.other | 5001 | en_US |
dc.identifier.other | 1884582 | en_US |
dc.identifier.uri | http://hdl.handle.net/11375/8810 | - |
dc.description.abstract | <p>This study was undertaken to explore the hypothesis<br />that dermatan sulfate, which catalyses thrombin inhibition by<br />heparin cofactor II, prevents thrombosis more effectively than<br />heparin, which catalyses thrombin inhibition by antithrombin<br />III. The rationale for this hypothesis is based upon three<br />general observations. First, higher doses of heparin are<br />required for the treatment of thrombus growth than are<br />required for the prevention of thrombus formation. Second,<br />thrombin bound to fibrin or to vessel wall components in vitro<br />is resistant to inhibition by heparin/antithrombin III.<br />Third, preliminary evidence indicates that the catalysis of<br />thrombin inhibition by antithrombin III-independent inhibitors<br />may be more effective than heparin/antithrombin III. The<br />results of this present study support the above hypothesis and<br />demonstrated that dermatan sulfate, a glycosaminoglycan which<br />catalyses thrombin inhibition by heparin cofactor II,<br />inhibited i) thrombus formation, ii) thrombus growth, and iii)<br />acted synergistically with tPA to enhance thrombolysis, more<br />effectively than heparin. These effects were achieved with minimal detrimental side-effects. These results indicate that<br />dermatan sulfate is an effective antithrombotic agent and<br />support the conclusion that the catalysis of thrombin<br />inhibition by dermatan sulfate/heparin cofactor II provides<br />a more effective pathway for preventing thrombus formation and<br />thrombus growth than the catalysis of thrombin inhibition by<br />heparin/antithrombin III.</p> | en_US |
dc.subject | Pharmacology | en_US |
dc.subject | Pharmacology | en_US |
dc.title | Dermatan Sulfate: A New Concept in Antithrombotic Therapy | en_US |
dc.type | thesis | en_US |
dc.contributor.department | Physiology and Pharmacology | en_US |
dc.description.degree | Doctor of Philosophy (PhD) | en_US |
Appears in Collections: | Open Access Dissertations and Theses |
Files in This Item:
File | Size | Format | |
---|---|---|---|
fulltext.pdf | 7.91 MB | Adobe PDF | View/Open |
Items in MacSphere are protected by copyright, with all rights reserved, unless otherwise indicated.